$189.52
2.27% today
NYSE, Oct 09, 09:45 pm CET
ISIN
US0758871091
Symbol
BDX

Becton, Dickinson & Stock price

$193.93
+2.35 1.23% 1M
-6.90 3.44% 6M
-32.94 14.52% YTD
-43.24 18.23% 1Y
-25.88 11.77% 3Y
-36.36 15.79% 5Y
+60.25 45.07% 10Y
+143.76 286.54% 20Y
NYSE, Closing price Wed, Oct 08 2025
+1.40 0.73%

Key metrics

Basic
Market capitalization
$55.6b
Enterprise Value
$74.2b
Net debt
$18.6b
Cash
$757.0m
Shares outstanding
286.6m
Valuation (TTM | estimate)
P/E
34.7 | 13.4
P/S
2.6 | 2.5
EV/Sales
3.5 | 3.4
EV/FCF
29.1
P/B
2.2
Dividends
DPS
$4.16
Yield 1Y | 5Y
2.2% | 1.5%
Growth 1Y | 5Y
9.5% | 6.2%
Payout 1Y | 3Y
64.9% | 65.3%
Increased
25 Years
Financials (TTM | estimate)
Revenue
$21.4b | $22.1b
EBITDA
$5.4b | $6.4b
EBIT
$3.0b | $5.4b
Net Income
$1.6b | $4.2b
Free Cash Flow
$2.6b
Growth (TTM | estimate)
Revenue
7.9% | 9.4%
EBITDA
4.0% | 24.0%
EBIT
2.5% | 86.7%
Net Income
13.7% | 144.2%
Free Cash Flow
-20.8%
Margin (TTM | estimate)
Gross
45.1%
EBITDA
25.4% | 29.2%
EBIT
14.1%
Net
7.5% | 18.9%
Free Cash Flow
11.9%
Financial Health
Equity Ratio
45.2%
Return on Equity
6.6%
ROCE
6.5%
ROIC
-
Debt/Equity
0.8
More
EPS
$5.6
FCF per Share
$8.9
Short interest
1.5%
Employees
74k
Rev per Employee
$270.0k
Show more

Is Becton, Dickinson & a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,998 stocks worldwide.

Becton, Dickinson & Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Becton, Dickinson & forecast:

8x Buy
44%
10x Hold
56%

Analyst Opinions

18 Analysts have issued a Becton, Dickinson & forecast:

Buy
44%
Hold
56%

Financial data from Becton, Dickinson &

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
21,386 21,386
8% 8%
100%
- Direct Costs 11,745 11,745
8% 8%
55%
9,641 9,641
7% 7%
45%
- Selling and Administrative Expenses 5,167 5,167
9% 9%
24%
- Research and Development Expense 1,244 1,244
6% 6%
6%
5,440 5,440
4% 4%
25%
- Depreciation and Amortization 2,419 2,419
6% 6%
11%
EBIT (Operating Income) EBIT 3,021 3,021
3% 3%
14%
Net Profit 1,606 1,606
14% 14%
8%

In millions USD.

Don't miss a Thing! We will send you all news about Becton, Dickinson & directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Becton, Dickinson & Stock News

Neutral
PRNewsWire
7 minutes ago
FRANKLIN LAKES, N.J. , Oct. 9, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m.
Neutral
PRNewsWire
about 10 hours ago
FRANKLIN LAKES, N.J. , Oct. 9, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the enrollment of the first patient in the XTRACT™ Registry, a prospective, multi-center, single-arm, post-market registry study designed to evaluate the real-world performance of the Rotarex™ Catheter System in the treatment of patient...
Neutral
PRNewsWire
one day ago
FRANKLIN LAKES, N.J. , Oct. 8, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Opentrons Labworks, Inc., recognized worldwide for accessible lab automation with more than 10,000 robotic systems deployed, today announced a multi-year collaboration.
More Becton, Dickinson & News

Company Profile

Becton, Dickinson & Co. is a medical technology company. The firm engages in the development, manufacture and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. It operates through the following segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via Homecare business. The company was founded in 1897 and is headquartered in Franklin Lakes, NJ.

Head office United States
CEO Thomas Polen
Employees 74,000
Founded 1897
Website www.bd.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today